Biogen’s new data, presented at the Alzheimer&#x27;s Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

BioSpace

Hello, and welcome to BioSpace's The Weekly. I'm your host, Jeff Axt. This week, all eyes are on the Alzheimer's Association International Conference, or AAIC. There, Biogen presented new data from its anti-tau therapy that industry watchers have lauded as validation for the anti-tau approach. Meanwhile, psychedelics are back in the news with more positive data from Compass Pathways as well as final guidance from the FDA.

And finally, in the ATTR-CM space, we got a major shakeup with the late-stage failure of AstraZeneca and Ionis' Antisense Therapeutic, which has cast out on Anilum's NextGen Candidate but could be good news for Bridge Bio and Antelia Therapeutics. Let's get started. Hi, guys. How are you doing? We are a short one this week with Annalie off visiting family, but glad to have you back, Gabby. Yesterday was real quiet around here with just me and Heather.

Happy to be back. I know Mondays are sometimes really hit or miss with news. So how was the news on Monday? Was it busy? It was actually quite slow. We were grateful for that, although concerned that we might not have enough to talk about today. Yes. Luckily, AAIC has come through. And then the psychedelics announcement that also kind of surprised me, that draft is three years old. So I didn't expect that news coming out this week. But anyways, yeah, we did end up with quite the lineup this week. We have plenty to talk about.

Yeah, definitely. AAIC has been my world the past week or so. I'm just prepping for it and talking to companies. And now all that is kind of funny. Now all that that data is coming out. And I'm like, you know, just kind of watching for the reactions of the analysts.

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.